Insulet (NASDAQ:PODD) Sees Strong Trading Volume

Insulet Co. (NASDAQ:PODD) shares saw strong trading volume on Friday . 466,851 shares were traded during trading, a decline of 44% from the previous session’s volume of 832,141 shares.The stock last traded at $187.95 and had previously closed at $190.88.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. OTR Global reiterated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Barclays reduced their target price on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Redburn Atlantic started coverage on Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $234.00 price target on shares of Insulet in a report on Tuesday. Finally, Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target for the company in a report on Tuesday, May 7th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $239.18.

Insulet Stock Up 2.3 %

The firm has a fifty day simple moving average of $193.12 and a 200-day simple moving average of $184.80. The company has a market capitalization of $13.68 billion, a P/E ratio of 57.84, a P/E/G ratio of 3.50 and a beta of 1.16. The company has a quick ratio of 2.75, a current ratio of 3.74 and a debt-to-equity ratio of 1.72.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. Insulet’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period last year, the company earned $0.23 earnings per share. On average, equities research analysts expect that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares in the company, valued at $2,574,485. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the completion of the sale, the senior vice president now directly owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mark N. Field sold 1,500 shares of Insulet stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The disclosure for this sale can be found here. Insiders sold a total of 13,931 shares of company stock worth $2,636,286 over the last ninety days. 0.47% of the stock is currently owned by corporate insiders.

Institutional Trading of Insulet

Several hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors lifted its holdings in Insulet by 19.7% during the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after purchasing an additional 1,556,455 shares during the last quarter. Vanguard Group Inc. increased its stake in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after acquiring an additional 169,506 shares during the period. Baillie Gifford & Co. increased its stake in Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after acquiring an additional 443,783 shares during the period. Norges Bank bought a new position in Insulet during the 4th quarter worth $227,655,000. Finally, William Blair Investment Management LLC increased its stake in Insulet by 3.7% during the 1st quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock worth $163,219,000 after acquiring an additional 33,579 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.